Newspaper Advertisement of financial results under regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Transgene Biotek Ltd has submitted to BSE the newspaper clippings of its unaudited financial results for the quarter and half year ended September 30, 2025, as required under SEBI Regulation 47 of the LODR Regulations, 2015. The results were published in Business Standard (English) and Navatelangana (Telugu) on November 15, 2025. The actual detailed financial figures for Transgene Biotek are not legible in the provided document text, but the full results would be available on the BSE website and the company's website. The letter was signed by Managing Director Dr K Koteswara Rao and dated November 20, 2025.
This is a routine regulatory compliance filing and does not contain any new material information beyond what was already disclosed in the original Q2/H1 results submission. No direct impact on the stock price is expected from this disclosure alone.